Open AccessSignificant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the glioblastoma multiforme patients in the backdrop of mutational status of epidermal growth factor receptor and PTEN Genes
Author(s) -
Sajad Arif,
Arshad A. Pandith,
Rehana Tabasum,
Altaf Ramzan,
Sarabjeet Singh,
Mushtaq A. Siddiqi,
Abdul Rashid Bhat
Publication year - 2018
Publication title -
asian journal of neurosurgery
Language(s) - English
Resource type - Journals
ISSN - 2248-9614
DOI - 10.4103/ajns.ajns_95_17
Subject(s) - pten , gefitinib , medicine , epidermal growth factor receptor , cancer research , tyrosine kinase inhibitor , oncology , tyrosine kinase , cancer , biology , signal transduction , receptor , pi3k/akt/mtor pathway , genetics
We aimed to assess the effect of anti-tyrosine kinase inhibitors (TKIs) (gefitinib) in overall survival (OS) of the glioblastoma multiforme (GBM) patients in the backdrop of mutational status of epidermal growth factor receptor ( EGFR ) and PTEN genes.